Praxis Precision Medicines Inc (PRAX)
$345.59
$-7.04
(-2.00%)
As on 29-May-2026 10:37EDT
Market cap
$9,578 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
6.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-6.9
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-13.8
-
Face value
--
-
Shares outstanding
27,878,774
6 Years Aggregate
CFO
$-527.50 Mln
EBITDA
$-631.41 Mln
Net Profit
$-627.10 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Praxis Precision Medicines Inc (PRAX)
| 17.3 | 7.4 | 2.6 | 833.3 | 184.5 | 3.3 | -- |
|
BSE Sensex
| -11.7 | -2.7 | -8.0 | -8.0 | 6.2 | 7.8 | 10.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Praxis Precision Medicines Inc (PRAX)
| 283.0 | 241.9 | -37.6 | -87.9 | -64.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Praxis Precision Medicines Inc (PRAX)
|
345.6 | 9,578.0 | 0.0 | -326.5 | -- | -37.2 | -- | 6.8 |
| 77.5 | 10,557.2 | 622.0 | -300.9 | -25.7 | -61.1 | -- | 17.3 | |
| 76.5 | 10,446.2 | 105.8 | -829.6 | -715.0 | -- | -- | 60.3 | |
| 51.3 | 12,605.5 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.6 | 6.4 | |
| 131.0 | 15,772.8 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 67.7 | 8,103.6 | 1,508.5 | 348.8 | 57.0 | 96.4 | 24 | 36.9 | |
| 311.7 | 8,827.7 | 417.3 | 225.0 | 42.8 | 18.6 | 40 | 6.9 | |
| 506.7 | 11,925.8 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 22.0 | |
| 446.2 | 12,360.6 | 2,678.3 | 460.4 | 21.1 | 103.2 | 27.3 | 20.7 | |
| 109.6 | 8,067.3 | 0.0 | -450.1 | -- | -44.6 | -- | 6.9 |
Shareholding Pattern
View DetailsAbout Praxis Precision Medicines Inc (PRAX)
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The... company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. Address: 99 High Street, Boston, MA, United States, 02110 Read more
-
President, CEO & Director
Mr. Marcio Silva De'Souza M.B.A.
-
President, CEO & Director
Mr. Marcio Silva De'Souza M.B.A.
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Praxis Precision Medicines Inc (PRAX)
What is the current share price of Praxis Precision Medicines Inc (PRAX) Today?
The share price of Praxis Precision Medicines Inc (PRAX) is $345.59 (NASDAQ) as of 29-May-2026 10:37 EDT. Praxis Precision Medicines Inc (PRAX) has given a return of 184.55% in the last 3 years.
What is the current PB & PE ratio of Praxis Precision Medicines Inc (PRAX)?
Since, TTM earnings of Praxis Precision Medicines Inc (PRAX) is negative, P/E ratio is not available.
The P/B ratio of Praxis Precision Medicines Inc (PRAX) is 6.80 times as on 22-May-2026, a 60 premium to its peers’ median range of 4.24 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-22.35
|
7.72
|
|
2024
|
-7.58
|
3.11
|
|
2023
|
-1.27
|
2.24
|
|
2022
|
-0.03
|
0.09
|
|
2021
|
-0.35
|
0.24
|
What is the 52 Week High and Low of Praxis Precision Medicines Inc (PRAX)?
The 52-week high and low of Praxis Precision Medicines Inc (PRAX) are Rs 366.52 and Rs 36.30 as of 29-May-2026.
What is the market cap of Praxis Precision Medicines Inc (PRAX)?
Praxis Precision Medicines Inc (PRAX) has a market capitalisation of $ 9,578 Mln as on 22-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Praxis Precision Medicines Inc (PRAX)?
Before investing in Praxis Precision Medicines Inc (PRAX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.